1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol, 2009, 16(10): 2682-2690.
|
3. |
Zhang BL, Sivasubramaniam PG, Zhang Q, et al. Trends in radical surgical treatment methods for breast malignancies in China: a multicenter 10-year retrospective study. Oncologist, 2015, 20(9): 1036-1043.
|
4. |
Huang NS, Liu MY, Chen JJ, et al. Surgical management of breast cancer in China: a 15-year single-center retrospective study of 18, 502 patients. Medicine (Baltimore), 2016, 95(45): e4201.
|
5. |
Zhang B, Song Q, Zhang B, et al. A 10-year (1999~2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. Breast, 2013, 22(5): 676-681.
|
6. |
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 2002, 347(16): 1233-1241.
|
7. |
Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med, 1995, 333(22): 1444-1455.
|
8. |
Sarrazin D, Lê MG, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol, 1989, 14(3): 177-184.
|
9. |
Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med, 1981, 305(1): 6-11.
|
10. |
van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst, 2000, 92(14): 1143-1150.
|
11. |
Poortmans P, Aznar M, Bartelink H. Quality indicators for breast cancer: revisiting historical evidence in the context of technology changes. Semin Radiat Oncol, 2012, 22(1): 29-39.
|
12. |
van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol, 2016, 17(8): 1158-1170.
|
13. |
de Boniface J, Frisell J, Bergkvist L, et al. Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation. Br J Surg, 2018, 105(12): 1607-1614.
|
14. |
de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg, 2021, 156(7): 628-637.
|
15. |
Wu SG, Wang Y, Zhou J, et al. Number of negative lymph nodes should be considered for incorporation into staging for breast cancer. Am J Cancer Res, 2015, 5(2): 844-853.
|
16. |
Lagendijk M, van Maaren MC, Saadatmand S, et al. Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129, 692 patients. Int J Cancer, 2018, 142(1): 165-175.
|
17. |
Wang J, Deng JP, Sun JY, et al. Noninferior outcome after breast-conserving treatment compared to mastectomy in breast cancer patients with four or more positive lymph nodes. Front Oncol, 2019, 9: 143.
|
18. |
van Maaren MC, de Munck L, Jobsen JJ, et al. Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients. Breast Cancer Res Treat, 2016, 160(3): 511-521.
|
19. |
de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet, 1993, 341(8852): 1039-1043.
|
20. |
Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer, 2012, 48(18): 3355-3377.
|
21. |
Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast, 2015, 24(3): 175-181.
|
22. |
Sinnadurai S, Kwong A, Hartman M, et al. Breast-conserving surgery versus mastectomy in young women with breast cancer in Asian settings. BJS Open, 2019, 3(1): 48-55.
|
23. |
DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42.
|
24. |
Rutter CE, Lester-Coll NH, Mancini BR, et al. The evolving role of adjuvant radiotherapy for elderly women with early-stage breast cancer. Cancer, 2015, 121(14): 2331-2340.
|
25. |
Ward MC, Vicini F, Chadha M, et al. Radiation therapy without hormone therapy for women age 70 or above with low-risk early breast cancer: a microsimulation. Int J Radiat Oncol Biol Phys, 2019, 105(2): 296-306.
|
26. |
Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial. Lancet Oncol, 2015, 16(3): 266-273.
|
27. |
Savard MF, Clemons M, Hutton B, et al. De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: a systematic review and meta-analysis. Cancer Treat Rev, 2021, 99: 102254.
|
28. |
Tringale KR, Berger ER, Sevilimedu V, et al. Breast conservation among older patients with early-stage breast cancer: locoregional recurrence following adjuvant radiation or hormonal therapy. Cancer, 2021, 127(11): 1749-1757.
|
29. |
Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst, 1999, 91(24): 2112-2117.
|
30. |
Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet, 2002, 359(9316): 1471-1477.
|
31. |
Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer, 2005, 103(1): 44-51.
|
32. |
Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage Ⅰ/Ⅱ breast cancer. J Clin Oncol, 2006, 24(16): 2437-2443.
|
33. |
Wan Q, Su L, Ouyang T, et al. Comparison of survival after breast-conserving therapy vs mastectomy among patients with or without the brca1/2 variant in a large series of unselected Chinese patients with breast cancer. JAMA Netw Open, 2021, 4(4): e216259.
|
34. |
van den Broek AJ, Schmidt MK, van’t Veer LJ, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg, 2019, 270(2): 364-372.
|
35. |
Huang X, Cai XY, Liu JQ, et al. Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population. Gland Surg, 2020, 9(3): 775-787.
|
36. |
Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat, 2010, 121(2): 389-398.
|
37. |
Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18(12): 1927-1934.
|
38. |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol, 2018, 19(1): 27-39.
|
39. |
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16(8): 2672-2685.
|
40. |
Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol, 2008, 26(5): 778-785.
|
41. |
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr, 2001(30): 96-102.
|
42. |
Mamtani A, Sevilimedu V, Le T, et al. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?. Cancer, 2022, 128(3): 471-478.
|
43. |
Wang J, Tang H, Yin K, et al. Second invasive breast cancers in patients treated with breast-conserving therapy. Eur J Surg Oncol, 2021, 47(10): 2492-2498.
|
44. |
Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol, 2006, 24(13): 2028-2037.
|
45. |
Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet, 1991, 338(8763): 327-331.
|
46. |
Bottero M, Borzillo V, Pergolizzi S, et al. The Italian association of radiotherapy and oncology recommendation for breast tumor recurrence: grades of recommendation, assessment, development and evaluation criteria. J Breast Cancer, 2021, 24(3): 241-252.
|
47. |
Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
|
48. |
Sellam Y, Shahadi ID, Gelernter I, et al. Local recurrence of breast cancer: salvage lumpectomy as an option for local treatment. Breast J, 2019, 25(4): 619-624.
|
49. |
Chen I, Botty Van den Bruele AM, Gillespie EF, et al. Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation. Breast Cancer Res Treat, 2021, 188(2): 409-414.
|
50. |
Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: the NRG Oncology/RTOG 1014 Phase 2 clinical trial. JAMA Oncol, 2020, 6(1): 75-82.
|
51. |
Houvenaeghel G, Boher JM, Michel V, et al. Survival after breast cancer local recurrence according to therapeutic strategies. Eur J Surg Oncol, 2017, 43(8): 1409-1414.
|
52. |
Smanykó V, Mészáros N, Újhelyi M, et al. Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results. Brachytherapy, 2019, 18(3): 411-419.
|
53. |
Hannoun-Levi JM, Resch A, Gal J, et al. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO breast cancer working group. Radiother Oncol, 2013, 108(2): 226-231.
|
54. |
Fodor J, Major T, Polgár C, et al. Prognosis of patients with local recurrence after mastectomy or conservative surgery for early-stage invasive breast cancer. Breast, 2008, 17(3): 302-308.
|
55. |
Su Y, Guo R, Xue J, et al. Increased mortality with repeat lumpectomy alone after ipsilateral breast tumor recurrence. Oncologist, 2019, 24(9): e818-e827.
|
56. |
Chen SL, Martinez SR: The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. Am J Surg, 2008, 196(4): 495-499.
|
57. |
Tralongo P, Surbone A, Serraino D, et al. Major patterns of cancer cure: clinical implications. Eur J Cancer Care (Engl), 2019, 28(6): e13139.
|
58. |
Janz NK, Mujahid M, Lantz PM, et al. Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer. Qual Life Res, 2005, 14(6): 1467-1479.
|
59. |
Ganz PA, Schag AC, Lee JJ, et al. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. Cancer, 1992, 69(7): 1729-1738.
|
60. |
Davis LE, Fulton C, Bubis LD, et al. Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study. Breast Cancer Res Treat, 2019, 175(3): 721-731.
|
61. |
Ng ET, Ang RZ, Tran BX, et al. Comparing quality of life in breast cancer patients who underwent mastectomy versus breast-conserving surgery: a meta-analysis. Int J Environ Res Public Health, 2019, 16(24): 4970.
|
62. |
Dominici L, Hu J, Zheng Y, et al. Association of local therapy with quality-of-life outcomes in young women with breast cancer. JAMA Surg, 2021, 156(10): e213758.
|